Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
2017
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
32
References
0
Citations
NaN
KQI